Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Acid Clinical Trials and EPA/DHA - a podcast by ReachMD

CME credits: 0.25

Valid until: 28-05-2022

Claim your CME credit at https://reachmd.com/programs/cme/understanding-differences-between-strength-and-reduce-it-omega-3-fatty-acid-clinical-trials-and-epadha/12618/

In 2019, the REDUCE-IT trial studying eicosapentaenoic acid (EPA), a purified form of omega-3 fatty acid, was published and demonstrated a dramatic 25% reduction in major cardiovascular events. In 2020, the STRENGTH trial that used a carboxylic acid formulation of combined EPA and docosahexaenoic acid (DHA), was surprisingly neutral and the study was halted for futility. A recent post hoc analysis of the STRENGTH study failed to show a difference in the primary endpoint in the highest tertile group receiving the EPA/DHA carboxylic acid treatment. Why did these two major omega-3 clinical trials studying patients with elevated triglyceride levels have disparate results? What does this mean for our patients? Join two experts, Drs. Michael Miller and Brian Olshansky, as they assess the different trials and offer their perspective on the clinical and scientific implications of the results.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD